Logo image of UNC.DE

UCB SA (UNC.DE) Stock Price, Forecast & Analysis

Europe - Frankfurt Stock Exchange - FRA:UNC - BE0003739530 - Common Stock

260.7 EUR
+6.1 (+2.4%)
Last: 1/14/2026, 7:00:00 PM

UNC.DE Key Statistics, Chart & Performance

Key Statistics
Market Cap50.71B
Revenue(TTM)6.85B
Net Income(TTM)1.33B
Shares194.51M
Float119.32M
52 Week HighN/A
52 Week LowN/A
Yearly Dividend1.36
Dividend Yield0.39%
EPS(TTM)6.42
PE40.61
Fwd PE25.5
Earnings (Next)02-26
IPO1987-01-02
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
UNC.DE short term performance overview.The bars show the price performance of UNC.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 2 4 6 8

UNC.DE long term performance overview.The bars show the price performance of UNC.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of UNC.DE is 260.7 EUR. In the past month the price increased by 6.76%.

UCB SA / UNC Daily stock chart

UNC.DE Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to UNC.DE.


Chartmill TA Rating
Chartmill Setup Rating

UNC.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to UNC.DE. Both the profitability and the financial health of UNC.DE get a neutral evaluation. Nothing too spectacular is happening here.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

UNC.DE Financial Highlights

Over the last trailing twelve months UNC.DE reported a non-GAAP Earnings per Share(EPS) of 6.42. The EPS increased by 75.41% compared to the year before.


Industry RankSector Rank
PM (TTM) 19.45%
ROA 7.75%
ROE 13.76%
Debt/Equity 0.29
Chartmill High Growth Momentum
EPS Q2Q%68.9%
Sales Q2Q%24.94%
EPS 1Y (TTM)75.41%
Revenue 1Y (TTM)25.56%

UNC.DE Forecast & Estimates

25 analysts have analysed UNC.DE and the average price target is 253.39 EUR. This implies a price decrease of -2.8% is expected in the next year compared to the current price of 260.7.

For the next year, analysts expect an EPS growth of 59.37% and a revenue growth 25.37% for UNC.DE


Analysts
Analysts76
Price Target253.39 (-2.8%)
EPS Next Y59.37%
Revenue Next Year25.37%

UNC.DE Ownership

Ownership
Inst Owners41.62%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A

UNC.DE Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
1SAN.MI SANOFI 10.85 200.25B
SNW.DE SANOFI 10.63 196.17B
SAN.PA SANOFI 10.63 196.21B
MRK.DE MERCK KGAA 15.24 56.52B
UCB.BR UCB SA 41.37 51.66B
1BAYN.MI BAYER AG-REG 7.74 40.61B
BAYN.DE BAYER AG-REG 7.77 40.79B
IPN.PA IPSEN 13.1 11.27B
TUB.BR FINANCIERE DE TUBIZE 113.22 10.48B
REC.MI RECORDATI INDUSTRIA CHIMICA 24.36 10.03B
VIRP.PA VIRBAC SA 20.59 3.00B
DMP.DE DERMAPHARM HOLDING SE 17.28 2.00B

Related stock screener links

About UNC.DE

Company Profile

UNC logo image UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 9,378 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

Company Info

UCB SA

Allee de la Recherche, 60

Anderlecht BRUXELLES-CAPITALE BE

Employees: 9215

UNC Company Website

UNC Investor Relations

Phone: 3225599999

UCB SA / UNC.DE FAQ

Can you describe the business of UCB SA?

UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 9,378 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.


What is the stock price of UCB SA today?

The current stock price of UNC.DE is 260.7 EUR. The price increased by 2.4% in the last trading session.


What is the dividend status of UCB SA?

UCB SA (UNC.DE) has a dividend yield of 0.39%. The yearly dividend amount is currently 1.36.


How is the ChartMill rating for UCB SA?

UNC.DE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


What is the analyst forecast for UNC.DE stock?

25 analysts have analysed UNC.DE and the average price target is 253.39 EUR. This implies a price decrease of -2.8% is expected in the next year compared to the current price of 260.7.


What is the next earnings date for UNC stock?

UCB SA (UNC.DE) will report earnings on 2026-02-26, after the market close.